Alvotech

Pipeline Approvals And Global Rollout Will Boost Biosimilar Markets

AnalystConsensusTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

05 May 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$17.50

48.6% undervalued

15 Aug

US$9.00

-30.7%

5.6%

Author's Valuation

US$17.5

48.6% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$17.5

48.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

25.95%

Biotech revenue growth rate

12.71%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.02%

Calculation

US$321.41m

Earnings '28

20.32x

PE Ratio '28

US$6.53b

Market Cap '28

US$6.53b

Market Cap '28

305.19m

No. shares '28

US$21.40

Share Price '28

US$21.40 Share Price '28

Discounted to 2025 @ 6.94% p.a.

US$17.50

Fair Value '25